bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice

Nature Medicine

Volumn 4, Issue 2, 1998, Pages 232-234

  Jansen, Burkhard ^a   Schlagbauer Wadl, Hermine ^a   Brown, Bob D ^b   Bryan, Robert N ^b   Van Elsas, Andrea ^c   Müller, Markus ^a   Wolff, Klaus ^a   Eichler, Hans Georg ^a   Pehamberger, Hubert ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b Genta Inc   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DACARBAZINE; PROTEIN BCL 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CHEMOSENSITIVITY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MELANOMA; MOUSE; PRIORITY JOURNAL; SCID MOUSE;

ACTINS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DACARBAZINE; FEMALE; HUMANS; MELANOMA; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSPLANTATION, HETEROLOGOUS;

EID: 0031907428     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0298-232     Document Type: Article

References (16)

1. Boring, C.C., Squires, T.S., Tong, T. & Montgomery, S. Cancer statistics 1994. CA: Cancer J. Clinic. 44, 7-26 (1994).
2. Hickman, J.A., Apoptosis and chemotherapy resistance. Eur. J. Cancer 32A, 921-926 (1996).
3. Cerroni, L., Soyer, H.P. & Kerl, H. bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi. Am. J. Dermatopathol. 17, 7-11 (1995).
4. Morales-Ducret, C.R.J., van deRijn, M., LeBrun, D.P. & Smoller. B.R. bcl-2 expression in primary malignancies of the skin. Arch. Dermatol. 131, 909-918 (1995).
5. Plettenberg, A. et al. Human melanocytes and melanoma cells constitutively express the Bcl-2 proto-oncogene in situ and in cell culture. Am. J. Pathol. 146, 651-659 (1995).
6. Tron, V.A. et al. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma. Am. J. Pathol. 146, 643-650 (1995).
7. Crover, R. & Wilson, G.D. Bcl-2 expression in malignant melanoma and its prognostic significance. Eur. J. Surg. Oncol. 22, 347-349 (1996).
8. Stein, C.A. & Cheng, Y.-C. Antisense oligonucleotides as therapeutic agents - Is the bullet really magical? Science 261, 1004-1012 (1993).
9. Stein, C.A. Does antisense exist? Nature Med. 1, 1119-1121 (1995).
10. Christoffersen, R.E. Translating genomics information into therapeutics: A key role for oligonucleotides. Nature Biotechnol. 15, 483-484 (1997).
11. Monia, B.P., Johnston, J.F., Geiger, T., Muller, M. & Fabbro, D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nature Med. 2, 668-675 (1996).
12. Comis, R.L. DTIC (NSC-45388) in malignant melanoma: A perspective. Cancer Treat. Rep. 60, 165-176 (1976).
13. Henry, S.P., Monteith, D. & Levin, A.A. Antisense oligonucleotide inhibitors for the treatment of cancer. 2. lexicological properties of phosphorothioate oligonucleotides. Anti-Cancer Drug Des. 12, 395-408 (1997).
14. Krieg, A.M. et al. CpG motifs in bacterial DMA trigger direct B-cell activation. Nature 374, 546-549 (1995).
15. Wooldridge, J.E., Ballas, Z., Krieg, A.M. & Weiner, G.J. Immunostimulatory oligonucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood, 89, 2994-2998 (1997).
16. Webb, A. et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349, 1137-1141 (1997).